• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血红蛋白变异性与血液透析患者全因死亡率：系统评价和荟萃分析。

Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis.

机构信息

Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.

出版信息

Nephrology (Carlton). 2019 Dec;24(12):1265-1272. doi: 10.1111/nep.13560. Epub 2019 Feb 28.

DOI:10.1111/nep.13560
PMID:30644618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6899589/
Abstract

AIM

Haemoglobin (Hb) variability has been reported to be associated with mortality in dialysis patients in some but not all studies. We aimed to establish the prognostic significance of Hb variability with all-cause mortality in haemodialysis patients through this meta-analysis.

METHODS

The Medline, Embase, Cochrane Library and Web of Science databases were searched for studies assessing the association between Hb variability and all-cause mortality in haemodialysis patients after adjustment for other covariates.

RESULTS

We included three studies of five cohorts with a total of 262 641 patients. Forest plots showed that the combined hazard ratio for all-cause mortality was 1.09 (95% CI = 1.01-1.08; P = 0.03) per 1 g/dL increase in Hb variability.

CONCLUSION

Based on the current evidence, our meta-analysis found an association between Hb variability and all-cause mortality in patients receiving haemodialysis therapy.

摘要

目的

血红蛋白（Hb）变异性已在一些研究中被报道与透析患者的死亡率相关，但并非所有研究都如此。本研究旨在通过荟萃分析确定 Hb 变异性与血液透析患者全因死亡率之间的预后意义。

方法

检索 Medline、Embase、Cochrane 图书馆和 Web of Science 数据库，以评估调整其他协变量后 Hb 变异性与血液透析患者全因死亡率之间的相关性的研究。

结果

共纳入三项研究，涉及五个队列，共 262641 名患者。森林图显示，Hb 变异性每增加 1g/dL，全因死亡率的综合危险比为 1.09（95%CI=1.01-1.08；P=0.03）。

结论

基于目前的证据，我们的荟萃分析发现血液透析治疗患者的 Hb 变异性与全因死亡率之间存在关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/c0e686ba595c/NEP-24-1265-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/4677c10225ec/NEP-24-1265-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/4d0a41d4bcea/NEP-24-1265-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/6de5d4fce619/NEP-24-1265-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/c6c0baa920d5/NEP-24-1265-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/c0e686ba595c/NEP-24-1265-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/4677c10225ec/NEP-24-1265-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/4d0a41d4bcea/NEP-24-1265-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/6de5d4fce619/NEP-24-1265-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/c6c0baa920d5/NEP-24-1265-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4825/6899589/c0e686ba595c/NEP-24-1265-g005.jpg

相似文献

1
Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis.血红蛋白变异性与血液透析患者全因死亡率：系统评价和荟萃分析。
Nephrology (Carlton). 2019 Dec;24(12):1265-1272. doi: 10.1111/nep.13560. Epub 2019 Feb 28.
2
Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis.终末期肾病前血红蛋白变异性预测透析转换患者终末期肾病后死亡率。
Am J Nephrol. 2017;46(5):397-407. doi: 10.1159/000484356. Epub 2017 Nov 7.
3
Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS).血红蛋白浓度与心血管疾病发生前后血液透析患者的生存情况：来自日本透析结局和实践模式研究（J-DOPPS）的队列研究。
BMJ Open. 2019 Sep 5;9(9):e031476. doi: 10.1136/bmjopen-2019-031476.
4
Association between haemoglobin level and all-cause mortality in haemodialysis patients: the link with inflammation and malnutrition.血液透析患者血红蛋白水平与全因死亡率之间的关联：与炎症和营养不良的联系。
Prilozi. 2007 Jul;28(1):81-95.
5
UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.英国肾脏注册机构第11次年度报告（2008年12月）：第9章 2007年英国接受透析治疗患者的血红蛋白、铁蛋白和促红细胞生成素：全国及各中心具体分析
Nephron Clin Pract. 2009;111 Suppl 1:c149-83. doi: 10.1159/000209998. Epub 2009 Mar 26.
6
The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry.透析前后血红蛋白水平差异与透析患者 1 年死亡率风险的关联。来自日本肾脏登记处全国队列研究的结果。
PLoS One. 2019 Jan 10;14(1):e0210533. doi: 10.1371/journal.pone.0210533. eCollection 2019.
7
Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels.血液透析患者的贫血与死亡率：预测贫血倾向评分与实际血红蛋白水平的相互作用
Nephrol Dial Transplant. 2006 Jun;21(6):1652-62. doi: 10.1093/ndt/gfk095. Epub 2006 Jan 31.
8
Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.ESA 低反应性和血红蛋白变异性与血液透析患者死亡率的关联。
Nephrol Dial Transplant. 2010 Nov;25(11):3701-6. doi: 10.1093/ndt/gfq287. Epub 2010 May 26.
9
Prediction of time-averaged concentration of haemoglobin in haemodialysis patients.血液透析患者血红蛋白时间平均浓度的预测
Nephrol Dial Transplant. 2003 Oct;18(10):2082-7. doi: 10.1093/ndt/gfg355.
10
A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.一项关于贫血作为血液透析患者危险因素作用的前瞻性多中心研究：MAR研究。
Nephrol Dial Transplant. 2007 Feb;22(2):500-7. doi: 10.1093/ndt/gfl558. Epub 2006 Oct 5.

引用本文的文献

1
Hemoglobin stability impact on healthcare resource utilization and costs among dialysis-dependent patients with anemia of end-stage kidney disease.血红蛋白稳定性对终末期肾病贫血依赖透析患者医疗资源利用及成本的影响
BMC Nephrol. 2025 Aug 18;26(1):466. doi: 10.1186/s12882-025-04390-y.
2
Effect of Erythropoiesis-Stimulating Agent Types on Hemoglobin Variability in Hemodialysis Patients.促红细胞生成素类型对血液透析患者血红蛋白变异性的影响。
J Clin Med. 2025 Jul 9;14(14):4863. doi: 10.3390/jcm14144863.
3
Computer-assisted prescription of erythropoiesis-stimulating agents in patients undergoing maintenance hemodialysis: a randomized control trial for artificial intelligence model selection.

本文引用的文献

1
Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.血红蛋白波动的患病率及其对接受血液透析和促红细胞生成素治疗的泰国终末期肾病患者预后的临床影响。
J Med Assoc Thai. 2016 Feb;99 Suppl 2:S28-37.
2
Blood pressure variability among chronic dialysis patients: recent advances in knowledge.慢性透析患者的血压变异性：知识的最新进展
Curr Opin Nephrol Hypertens. 2015 Mar;24(2):163-9. doi: 10.1097/MNH.0000000000000107.
3
Optimization of anemia treatment in hemodialysis patients via reinforcement learning.
维持性血液透析患者促红细胞生成素刺激剂的计算机辅助处方：人工智能模型选择的随机对照试验
JAMIA Open. 2025 Mar 27;8(2):ooaf020. doi: 10.1093/jamiaopen/ooaf020. eCollection 2025 Apr.
4
Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study.促红细胞生成素刺激剂反应性和血红蛋白变异性与接受达贝泊汀-α治疗的血液透析患者的脂肪组织指数相关：一项前瞻性观察队列研究。
Kidney Res Clin Pract. 2025 Mar;44(2):299-309. doi: 10.23876/j.krcp.24.070. Epub 2024 Dec 31.
5
Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.贫血控制模型的使用与血液透析患者住院风险降低相关。
Biomedicines. 2024 Sep 28;12(10):2219. doi: 10.3390/biomedicines12102219.
6
Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.个体化贫血治疗对血红蛋白稳定性的影响：一项针对血液透析患者的随机对照试验
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1138-1147. doi: 10.2215/CJN.0000000000000488. Epub 2024 Jun 11.
7
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.罗沙司他与红细胞生成刺激剂治疗非透析依赖或透析相关慢性肾脏病贫血患者的安全性：四项 3 期研究的汇总分析。
Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7.
8
Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study.贫血生物标志物与合并或不合并糖尿病的血液透析患者的死亡率：一项 10 年随访研究。
PLoS One. 2023 Jan 31;18(1):e0280871. doi: 10.1371/journal.pone.0280871. eCollection 2023.
9
Low-Dose Oral Iron Replacement Therapy Is Effective for Many Japanese Hemodialysis Patients: A Retrospective Observational Study.低剂量口服铁剂替代疗法对许多日本血液透析患者有效：一项回顾性观察研究。
Nutrients. 2022 Dec 27;15(1):125. doi: 10.3390/nu15010125.
10
Is Hemoglobin Concentration a Linear Predictor of Mortality in Older Adults From Chinese Longevity Regions?血红蛋白浓度是否可线性预测中国长寿地区老年人的死亡率？
Front Public Health. 2021 Nov 29;9:787935. doi: 10.3389/fpubh.2021.787935. eCollection 2021.
通过强化学习优化血液透析患者的贫血治疗。
Artif Intell Med. 2014 Sep;62(1):47-60. doi: 10.1016/j.artmed.2014.07.004. Epub 2014 Jul 19.
4
Prediction of the hemoglobin level in hemodialysis patients using machine learning techniques.运用机器学习技术预测血液透析患者的血红蛋白水平。
Comput Methods Programs Biomed. 2014 Nov;117(2):208-17. doi: 10.1016/j.cmpb.2014.07.001. Epub 2014 Jul 14.
5
Predialysis systolic BP variability and outcomes in hemodialysis patients.血液透析患者透析前收缩压变异性与结局。
J Am Soc Nephrol. 2014 Apr;25(4):799-809. doi: 10.1681/ASN.2013060667. Epub 2014 Jan 2.
6
Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s).KDIGO 贫血指南摘要及评论：字里行间的解读。
Kidney Int. 2012 Nov;82(9):952-60. doi: 10.1038/ki.2012.270. Epub 2012 Aug 1.
7
Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.在接受透析治疗的贫血患者中，血红蛋白和剂量的个体间变异性与使用的促红细胞生成刺激剂无关：一项荟萃分析。
Br J Clin Pharmacol. 2013 Jan;75(1):15-25. doi: 10.1111/j.1365-2125.2012.04383.x.
8
Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease.用于终末期肾病贫血管理方案设计的红细胞生成模型简化
Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:83-6. doi: 10.1109/IEMBS.2011.6089902.
9
Predictive modeling for improved anemia management in dialysis patients.预测模型可改善透析患者的贫血管理。
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):573-6. doi: 10.1097/MNH.0b013e32834bba4e.
10
Hemoglobin variability as a predictor of mortality: What's a practitioner to do?血红蛋白变异性作为死亡率的预测指标：从业者该怎么做？
Am J Kidney Dis. 2011 Feb;57(2):190-3. doi: 10.1053/j.ajkd.2010.11.004.